Qingda Affiliated Courtyard opened the first batch of third -generation ALK inhibitors in Shandong!This innovation therapy officially benefits from Shandong patients

Qingdao Daily/Guanhai News, June 15th. Today, Qingda Affiliated Courtyard opened the prescription of "the world's first third -generation ALK inhibitor Loladininib tablet (Borina®)". The first prescription in Shandong marks that ALK -positive advanced non -small cell lung cancer (NSCLC) global innovation therapy has officially benefited from Shandong patients.

Borrina® is a Berry of Pfizer's innovative drugs. It is a tyrosine kinase inhibitor (TKI) with a unique small molecular large -cycle -based amide structure. It has better anti -tumor activity, intracranial penetration and anti -drug activity. On April 27 this year, the State Drug Administration officially approved the treatment of Borrina® single medicines for inter -degenerative lymphoma kinase (ALK) positive local advanced or metastatic NSCLC patients, becoming a major in the history of ALK -positive NSCLC treatment in my country Milestone breakthrough.

In China, the incidence and mortality of lung cancer are the first, and the burden of disease is increasing. Non-small cell lung cancer is the most common type of lung cancer. About 3-7%of patients with non-small cell lung cancer have ALK gene mutations and are relatively small categories of patients with lung cancer subtype. ALK-positive late-stage non-small cell lung cancer patients are 52 years old, and they are in the golden period with strong age. The data shows that about 20-40%of ALK-positive late NSCLC patients have developed brain metastases at the initial diagnosis, and the incidence rate is extended over time over time. The rise brings severe challenges to the survival of patients.

However, ALK gene mutations are also called "diamond mutations". Such patients have a good effect on targeted drugs. With the emergence of ALK inhibitors, the disease of ALK -positive non -small cell lung cancer patients has been well controlled. Professor Lu Navy, director of the Department of Oncology, Affiliated Hospital Affiliated Hospital of Qingdao University, introduced: "With the launch of the domestic first and second -generation ALK inhibitors, the patient's median no progressive survival time has continued to extend. Some problems are difficult to solve, especially in the commonly used G1202R mutations. With the listing of Borina, the patient's urgent needs for patients' intracranial treatment and drug resistance will be better met. Progress provides excellent solutions. "

"At present, there are already classic drugs in the field of ALK -positive non -small cell lung cancer in the market in the market, and the second -generation Alantinib, etc., but clinically treats patients with brain metastases and first -generation, second -generation ALK inhibitors Patients still have serious unimpeded needs, and Loladinib's approval listing can just fill this clinical gap, realize the treatment of patients with brain metastases and first -generation, second -generation patients, and help improve such patients The non -progressive survival period reduces their disease progress or risk of death. "The Lu Navy said that Lolatinib can enter medical insurance as soon as possible to improve patients' accessibility, while promoting the upgrading of clinical drugs. At the same time, you can also strive for longer survival for more patients. (Qingdao Daily/Guanhai Journalist Guo Jingli)

- END -